



Meet Holly

AGE

43

LOCATION

FLORIDA

DIAGNOSED WITH MODERATE-TO-SEVERE  
PLAQUE PSORIASIS

1998

STARTED ILUMYA® (TILDRAKIZUMAB) 100 MG/ML

JUNE 2020

## Psoriasis Journey

Holly began her journey with moderate-to-severe plaque psoriasis in college when she started to notice plaques appear on her neck. It wasn't until she was in her 30s that Holly started to develop plaques on her forearms and legs.

She had no prior knowledge of moderate-to-severe plaque psoriasis and was unaware that this could cause internal effects in addition to causing visible plaques on the body.

Holly's moderate-to-severe plaque psoriasis symptoms put limitations on everyday choices like which color shirt to wear or how she wore her hair.

As a first-grade teacher, she was forced to focus on the itchiness of her plaques while in the classroom.

After her diagnosis, Holly tried other treatments to manage her symptoms but she was unable to find the correct treatment for her.

“ Moderate-to-severe plaque psoriasis was a frustrating and annoying diagnosis. ”

## Finding ILUMYA®

Holly's dermatologist introduced her to ILUMYA® and explained that it was different from her previous treatments because it is a biologic treatment that will target moderate-to-severe plaque psoriasis at its source.

“ After struggling with my skin for so long, feeling happy about my skin is a big deal and immeasurable. ”

After conducting her own research about dosing and side effects, Holly decided to take her dermatologist's advice and start treatment with ILUMYA®.

After her first two doses, Holly noticed that her plaques were clearing up and she no longer experienced itchiness.

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy. The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%). These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice.

## Road to Lasting Skin Clearance

Without symptoms of moderate-to-severe plaque psoriasis, Holly feels more comfortable in shorts, can wear her hair down freely and is able to keep up with her kids' busy schedules.

For Holly, it was important to find a treatment that would not only address her moderate-to-severe plaque psoriasis symptoms, but that had a dosing schedule that fits within her lifestyle. With just four doses a year after two starter doses, Holly can continue to shuttle her children from dance class and soccer practice without missing a dose.

At the gym or in Pilates class, Holly no longer has to worry about leaving plaques behind on her workout machine.

People living with moderate-to-severe psoriasis should talk to their doctor to determine what treatment option may be right for them. For more information about ILUMYA®, and a downloadable doctor discussion guide, visit [ILUMYA.com/talk-with-your-dermatologist](https://www.sunpharma.com/talk-with-your-dermatologist).

Learn more about the moderate-to-severe plaque psoriasis journeys of patients like Holly [here](#).

ILUMYA® IS IN IT FOR THE LONG HAUL WITH ME



With ILUMYA®, most people with moderate-to-severe plaque psoriasis can achieve clear or almost clear skin in as little as 12 weeks, and 5 years into treatment, it's still going strong.

Here are some reasons to ask your doctor about ILUMYA®:

- ✓ **LONG-LASTING RESULTS**  
9 out of 10 people who achieved clear or almost clear skin after 1 year were still seeing results 5 years later
- 📅 **DOSING AROUND YOUR SCHEDULE**  
4 doses a year after 2 starter doses

- 👤 **WORKS FROM THE INSIDE**  
ILUMYA® works with the body to balance an overactive immune system, addressing symptoms at the source
- 💰 **AFFORDABLE TREATMENT**  
Eligible patients may pay just \$5 per dose of ILUMYA®\*

\* \$16,000 maximum program benefit per calendar year. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE.

### What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

### IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
- are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit [www.fda.gov/medwatch](https://www.fda.gov/medwatch) or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or [drug.safetyUSA@sunpharma.com](mailto:drug.safetyUSA@sunpharma.com) (preferred) with as much information as available.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for ILUMYA and discuss any questions with your doctor.